Prothena Corporation plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTA research report →
Range $30 – $30
Price Chart
About the company
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.
- CEO
- Gene G. Kinney
- IPO
- 2012
- Employees
- 67
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on PRTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $422.10M
- P/E
- -17.68
- Fwd P/E
- 4.43
- PEG
- -0.06
- P/S
- 8.09
- P/B
- 1.59
- EV/EBITDA
- -6.92
- Div Yield
- 0.00%
- Gross Margin
- 96.47%
- Op Margin
- -78.40%
- Net Margin
- -45.43%
- ROE
- -8.34%
- ROIC
- -15.03%
Latest fiscal year · YoY change
- Revenue
- $9.68M-92.8%
- Gross Profit
- $5.98M-95.6%
- Op Income
- $-184,560,000
- Net Income
- $-244,092,000-99.6%
- EPS
- $-4.53-99.6%
- OCF Growth
- -9.0%
- FCF Growth
- -8.9%
- 52W High
- $11.80
- 52W Low
- $7.70
- 50D MA
- $8.45
- 200D MA
- $9.16
- Beta
- -0.33
- RSI (14)
- 46
- Avg Volume
- 480.31K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Prothena ended 2025 with a strong cash position and multiple partnered programs advancing, while 2026 is positioned around milestone catalysts, CYTOPE updates, and a share redemption program.· February 19, 2026
- Roche advanced prasinezumab and Novo Nordisk advanced coramitug into Phase III, extending Prothena’s partnered pipeline into late-stage development.
- Prothena highlighted up to $105 million of potential clinical milestones in 2026 from coramitug enrollment progress and BMS’s decision on PRX019.
- The company’s cash, cash equivalents and restricted cash were $308.4 million at year-end 2025, with zero debt.
- Management emphasized CYTOPE as a new platform opportunity, with TDP-43 data in ALS and early partnering interest beyond neuroscience.
- PRX012 transferrin remains a key preclinical focus after prior ASCENT data showed strong amyloid lowering but noncompetitive ARIA-E rates.
For 2025, net cash used in operating and investing activities was $163.7 million, better than guidance of $170 million to $178 million. Net loss was $244.1 million, in line with guidance of $240 million to $248 million. Year-end cash, cash equivalents and restricted cash were $308.4 million, above the guided $298 million, and the company ended with 0 debt. For 2026, Prothena guided to net cash used in operating and investing activities of $50 million to $55 million and expects to end the year with about $255 million in cash, cash equivalents and restricted cash. The 2026 guidance excludes up to $105 million of potential partner milestones tied to coramitug and PRX019.
Gene Kinney framed 2025 as a year of meaningful pipeline progress, with two partner programs moving into Phase III and the company’s CYTOPE technology emerging as a new platform. He stressed that 2026 will be busy, with scientific updates on TDP-43 CYTOPE, possible PRX019 and coramitug milestones, and implementation of a share redemption program. His tone was confident and constructive, repeatedly emphasizing long-term value creation, scientific validation, and a well-capitalized balance sheet.
Tran Nguyen said 2025 results were in line with or favorable to guidance, pointing to $163.7 million of net cash used in operating and investing activities versus guidance of $170 million to $178 million, and a net loss of $244.1 million versus guidance of $240 million to $248 million. He highlighted $308.4 million in cash, cash equivalents and restricted cash at December 31, 2025, and reiterated that Prothena has 0 debt. For 2026, he guided to $50 million to $55 million of net cash used in operating and investing activities, with an expected year-end cash balance of about $255 million, and noted this does not include potential milestone payments of up to $105 million.
Analysts focused on the timing and catalysts for the partnered programs, the path for PRX012 and its transferrin version, and what evidence would be needed to partner or advance the CYTOPE platform. Management said major visible milestones include CYTOPE scientific presentations in 2026, BMS TargetTau-1 data in the first half of 2027, and Phase III readouts for prasinezumab and coramitug in 2029. On PRX012, management argued the transferrin approach could improve ARIA-E while preserving convenient subcutaneous dosing; on CYTOPE, they said the platform appears broadly applicable and is already attracting research collaborations. For PRX019, they said the data belong to Bristol Myers Squibb and any public disclosure would be up to BMS.
The call underscored several ways Prothena could generate value without heavy internal spending: partner milestones, royalties, and potential new collaborations around CYTOPE. Management sounded encouraged by the Phase II data behind prasinezumab and coramitug, and by the potential for PRX012 transferrin to improve the profile of a once-monthly subcutaneous antibody. The balance sheet also gives the company room to pursue its 2026 priorities while keeping a simple capital structure with no debt.
Two key partnered Phase III trials will not complete until 2029, so much of the value proposition remains dependent on long-dated readouts. PRX012 still faces an unresolved safety question because prior data showed noncompetitive ARIA-E rates, and management said the transferrin approach still needs to be proven in study. CYTOPE is promising but early, with commercialization and partnering still at the research-collaboration stage rather than clinical validation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.5%
- Shares Outstanding
- 51.35M
- Float Shares
- 43.92M
of shares held by institutions
198 13F filers
Buy/sell ratio 9.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.01M | ▼ 184.85K |
| Blackrock, Inc. | 5.74M | ▲ 868.04K |
| Rubric Capital Management LP | 5.00M | 0 |
| Vanguard Group Inc | 2.14M | ▲ 91.06K |
| Acadian Asset Management LLC | 2.07M | ▲ 58.12K |
| State Street Corp | 1.84M | ▼ 551.75K |
| D. E. Shaw & Co., Inc. | 1.61M | ▼ 151.89K |
| Vanguard Portfolio Management LLC | 1.57M | ▼ 81.77K |
| Adar1 Capital Management, LLC | 1.55M | ▼ 26.91K |
| Two Sigma Investments, LP | 1.26M | ▲ 59.01K |
| Palo Alto Investors LP | 1.14M | ▼ 65.41K |
| Federated Hermes, Inc. | 1.14M | ▲ 53.86K |
Held by 162 ETFs
Biggest fund positions in PRTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | SCULLY WILLIAM P | buy | 50,000 |
| Nov 6, 26 | Fennell Todd W. | other | 0 |
| Nov 9, 26 | SCULLY WILLIAM P | buy | 140,000 |
| Nov 6, 26 | SCULLY WILLIAM P | other | 916,444 |
| Oct 27, 26 | SCULLY WILLIAM P | other | 566,444 |
| Oct 23, 26 | SCULLY WILLIAM P | buy | 50,000 |
| Oct 22, 26 | SCULLY WILLIAM P | buy | 100,000 |
| Oct 14, 26 | SCULLY WILLIAM P | buy | 10,000 |
| Oct 13, 26 | SCULLY WILLIAM P | buy | 100,000 |
| Oct 8, 26 | SCULLY WILLIAM P | buy | 90,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRTA coverage
Recent articles, reports, and earnings notes.
No research on PRTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRTA report →Insider Buying Signals: 3 Healthcare Stocks to Watch
investorplace.com · Nov 11
Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?
zacks.com · Nov 10
Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Target Price of $20.00
defenseworld.net · Nov 7
Prothena Reports Third Quarter 2026 Financial Results and Business Highlights
businesswire.com · Nov 5
Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares of Company Stock
defenseworld.net · Oct 27
Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Stock
defenseworld.net · Oct 27
Prothena (NASDAQ:PRTA) Shares Break Below Two Hundred Day Moving Average – What’s Next?
defenseworld.net · Oct 23
Prothena's Partnership Strategy: Growth Driver or Limitation?
zacks.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.